Rafferty Asset Management
TPTX

Rafferty Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Rafferty Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-39,251
Closed -$2.95M – 1292
2022
Q2 		$2.95M Sell
39,251
-153,875
-80% -$6.84M 0.03% 397
2022
Q1 		$5.18M Buy
193,126
+58,489
+43% +$1.97M 0.03% 383
2021
Q4 		$6.42M Buy
134,637
+91,821
+214% +$4.11M 0.03% 284
2021
Q3 		$2.84M Buy
42,816
+8,000
+23% +$570K 0.02% 511
2021
Q2 		$2.72M Buy
34,816
+5,758
+20% +$426K 0.02% 542
2021
Q1 		$2.75M Buy
29,058
+21,199
+270% +$2.52M 0.02% 542
2020
Q4 		$958K Sell
7,859
-17,350
-69% -$1.9M 0.01% 510
2020
Q3 		$2.2M Buy
25,209
+15,116
+150% +$1.05M 0.03% 386
2020
Q2 		$652K Buy
+10,093
New +$582K 0.01% 646
2020
Q1 		– Sell
-27,392
Closed -$1.71M – 854
2019
Q4 		$1.71M Buy
27,392
+2,211
+9% +$105K 0.03% 435
2019
Q3 		$947K Buy
+25,181
New +$1.1M 0.01% 554

Rafferty Asset Management's TPTX Position: Q3 2022 in Review

Rafferty Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 39,251 shares — an estimated $2.95M sold.

Rafferty Asset Management first reported a position in TPTX in Q3 2019 and held it in 11 quarters. The position peaked at $6.42M in Q4 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Rafferty Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 39,251 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2.95M.
  • Rafferty Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
  • Rafferty Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $6.42M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Rafferty Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.